Despite promising clinical results, copyright's Vyndamax, a treatment for hereditary transthyretin-mediated amyloidosis (hATTR), is experiencing substantial opposition from managed care entities. The insurers are often building obstacles to reimbursement, including high expense restrictions and approval processes that hinder user opportunity. Ma… Read More